Search
for
Sort by
Research 211–240 of 880
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- Reply
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Alopecia Areata Update
- Alopecia areata: An update
- Alopecia Areata
- Camouflage technique for alopecia areata: What is a patient to do?
- Frontal Fibrosing Alopecia: Update and Review of Challenges and Successes
- Nonsurgical Therapy for Hair Loss
- Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases
- Diseases of Periocular Hair
- Use of genetics in the prediction of success in male pattern hair loss therapy and mechanistic studies
- Hair Changes due to Drugs
- Selected topics in pediatric hair loss
- Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Alopecia areata: a new treatment plan
- The prostamide‐related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias
- Recent Progress in Prostaglandin F<sub>2</sub><i><sub>α</sub></i>Ethanolamide (Prostamide F<sub>2</sub><i><sub>α</sub></i>) Research and Therapeutics
- Adipose Tissue‐Derived Exosomes in the Treatment of Lichen Planopilaris: A Case Report
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
- Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Treating Alopecia Areata: Current Practices Versus New Directions
- Alopecia areata-like hair loss after a tick bite
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience